News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SynCo Bio Partners B.V. Signs Pharmaceutical Service Agreement With ProSensa B.V. for RNA Based Therapeutics for the Treatment of Duchenne Muscular Dystrophy


4/17/2007 11:06:33 AM

AMSTERDAM, April 17 /PRNewswire/ -- SynCo Bio Partners and Prosensa announce today their agreement to collaborate in the formulation and fill of RNA based therapeutics for the treatment of Duchenne Muscular Dystrophy (DMD).

Prosensa, a clinical stage biopharmaceutical company and SynCo Bio Partners, the leading biopharmaceuticals manufacturer are to collaborate on the formulation and fill of Prosensa's lead product, an RNA based therapeutic under development for the treatment of DMD.

Under the terms of the agreement, SynCo will work with Prosensa to formulate and performed the aseptic fill of an RNA based product for use in human clinical trial.

Gerard Platenburg, CEO of Prosensa commented, "We are very pleased to be working with SynCo, a company with a strong track record in providing first class GMP manufacturing services"

Pierre Warffemius, CEO of SynCo commented, "SynCo is pleased to be working with Prosensa on this important clinical program for the life saving treatment of DMD. We aim to establish a long-term relationship with Prosensa to support their expanding portfolio of nucleic acid based therapeutics against neuromuscular disorders, by providing high quality aseptic formulation and filling services"

About Prosensa

Prosensa B.V., a young Dutch Biopharmaceutical Company focused on the discovery, development and commercialization of nucleic acid based therapeutics correcting gene expression diseases with large unmet medical needs, in particular neuromuscular disorders. Prosensa is working closely with the research group of the Leiden University Medical Centre Department of Human Genetics, head professor Dr. G.J.B. van Ommen.

The Company is focused on developing a treatment for DMD (Duchenne Muscular Dystrophy). DMD is a genetic lethal childhood's disease with an incidence of approximately 1 in 3,500 new born boys. Clinical signs of muscle weakness start as early as 2 years of age affecting all muscles. Treatment of patients with DMD to date primarily involves supportive therapy. No curative treatment, re-establishing the function of dystrophin, the protein that is lacking in DMD patients, is yet available. For further information please visit the company's website at www.prosensa.eu

About SynCo Bio Partners

Synco Bio Partners B.V., a leading, contract manufacturing organization, is focused on the manufacture, development and aseptic filling of biopharmaceuticals. SynCo has a strong track record in the production and fill of recombinant proteins and vaccines. SynCo offers a fully integrated range of services in manufacturing and supports biopharmaceutical companies from the earliest stage in process development, through clinical trials to market supply. Established in 2000 and privately owned, SynCo collaborates with a number of leading biopharmaceutical companies, in Europe and the USA. Approximately 120 employees are based at the company's headquarters and manufacturing facility in Amsterdam, the Netherlands. Here, SynCo's activities include analytical and process development for new products, manufacture of Active Pharmaceutical Ingredients for licensed products and clinical trials, and aseptic filling and lyophilisation (for clinical trials and market supply). For further information please visit the company's website at www.syncobio.com

SynCo Bio Partners B.V.

CONTACT: For further details, please contact: Synco Bio Partners B.V.,Andrew Lewin, Business Development Director,Andrew_lewin@synco-biopartners.com, Tel: +31-(0)-207503607; Prosensa B.V.,Diana de Man, Communication, h.bastiaanse@prosensa.nl, Tel:+31-(0)-715276108


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES